Movatterモバイル変換

[0]ホーム
URL:

ECSP12011845A - Nuevos inhibidores macrocíclicos de la replicación - Google Patents

Nuevos inhibidores macrocíclicos de la replicación

Info

Publication number
ECSP12011845A
ECSP12011845AECSP12011845AECSP12011845AEC SP12011845 AECSP12011845 AEC SP12011845AEC SP12011845 AECSP12011845 AEC SP12011845AEC SP12011845 AECSP12011845 AEC SP12011845A
Authority
EC
Ecuador
Prior art keywords
replication
methods
macrocyclic inhibitors
new macrocyclic
treat
Prior art date
Application number
Other languages
English (en)
Inventor
Scott D Seiwert
Leonid Beigelman
Antitsa Dimitrova Stoycheva
Vladimir Serebryany
John B Nicholas
Timothy Thrailkill
Original Assignee
Intermune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intermune IncfiledCriticalIntermune Inc
Publication of ECSP12011845ApublicationCriticalpatent/ECSP12011845A/es

Links

Classifications

Landscapes

Abstract

Las configuraciones ofrecen compuestos de las formulas generales I, Ia, II, III, IV, V, VI-1, VI-2, VII, VIII, IX, X, XI, y XII, así como también composiciones, inclusive farmacéuticas, que incluyen un compuesto sujeto. Además, las configuraciones ofrecen métodos de tratamiento, inclusive métodos para tratar una infección del virus de la hepatitis C y métodos para tratar fibrosis hepática, conforme a los cuales, por lo general, se administra a un individuo que lo necesita una cantidad efectiva de un compuesto sujeto o de una composición sujeto.
ECSP120118452009-09-282012-04-27Nuevos inhibidores macrocíclicos de la replicaciónECSP12011845A (es)

Applications Claiming Priority (4)

Application NumberPriority DateFiling DateTitle
US24646509P2009-09-282009-09-28
US32425110P2010-04-142010-04-14
US34573710P2010-05-182010-05-18
US34623810P2010-05-192010-05-19

Publications (1)

Publication NumberPublication Date
ECSP12011845Atrue ECSP12011845A (es)2012-06-29

Family

ID=43796242

Family Applications (1)

Application NumberTitlePriority DateFiling Date
ECSP12011845ECSP12011845A (es)2009-09-282012-04-27Nuevos inhibidores macrocíclicos de la replicación

Country Status (19)

CountryLink
US (1)US20110081315A1 (es)
EP (1)EP2483290A4 (es)
JP (1)JP2013505952A (es)
KR (1)KR20130026410A (es)
CN (2)CN102741270B (es)
AR (1)AR078462A1 (es)
AU (1)AU2010298028A1 (es)
CA (1)CA2775697A1 (es)
CO (1)CO6531497A2 (es)
EA (1)EA201290128A1 (es)
EC (1)ECSP12011845A (es)
IL (1)IL218766A0 (es)
IN (1)IN2012DN02693A (es)
MA (1)MA33720B1 (es)
MX (1)MX2012003500A (es)
PH (1)PH12012500602A1 (es)
TN (1)TN2012000135A1 (es)
TW (1)TW201124137A (es)
WO (1)WO2011038293A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
EP1924594A2 (en)2005-07-252008-05-28Intermune, Inc.Novel macrocyclic inhibitors of hepatitis c virus replication
EA200801050A1 (ru)*2005-10-112008-12-30Интермьюн, Инк.Соединения и способы ингибирования репликации вирусного гепатита с
AP2010005416A0 (en)*2008-04-152010-10-31Intermune IncNovel macrocyclic inhibitors of hepatitis c virus replication.
CA2740728A1 (en)*2008-10-152010-04-22Intermune, Inc.Therapeutic antiviral peptides
US20110082182A1 (en)*2009-10-012011-04-07Intermune, Inc.Therapeutic antiviral peptides
ES2586231T3 (es)*2010-03-032016-10-13Probiodrug AgInhibidores de glutaminil ciclasa
CA2801584A1 (en)2010-06-072011-12-15Abbvie Inc.Macrocyclic hepatitis c serine protease inhibitors
CA2811025C (en)*2010-09-102018-07-17Shionogi & Co., Ltd.Hetero ring-fused imidazole derivative having ampk activating effect
WO2012054874A1 (en)*2010-10-222012-04-26Intermune, Inc.Novel macrocyclic inhibitors of hepatitis c virus replication
US8957203B2 (en)2011-05-052015-02-17Bristol-Myers Squibb CompanyHepatitis C virus inhibitors
US8691757B2 (en)2011-06-152014-04-08Bristol-Myers Squibb CompanyHepatitis C virus inhibitors
EP2758386A1 (en)*2011-09-222014-07-30Janssen Pharmaceuticals, Inc.Processes and intermediates for preparing a macrocyclic protease inhibitor of hcv
MX2014015265A (es)2012-06-142015-08-12Basf SeMetodos plaguicidas que utilizan compuestos de 3-piridiltiazol sustituido y derivados para combatir plagas de animales.
UA119315C2 (uk)2012-07-032019-06-10Гіліад Фармассет ЕлелсіІнгібітори вірусу гепатиту с
KR20150074051A (ko)2012-10-192015-07-01브리스톨-마이어스 스큅 컴퍼니C형 간염 바이러스 억제제
WO2014070964A1 (en)2012-11-022014-05-08Bristol-Myers Squibb CompanyHepatitis c virus inhibitors
WO2014071007A1 (en)2012-11-022014-05-08Bristol-Myers Squibb CompanyHepatitis c virus inhibitors
US9643999B2 (en)2012-11-022017-05-09Bristol-Myers Squibb CompanyHepatitis C virus inhibitors
US9409943B2 (en)2012-11-052016-08-09Bristol-Myers Squibb CompanyHepatitis C virus inhibitors
JP6342922B2 (ja)2013-03-072018-06-13ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ ＣｏｍｐａｎｙＣ型肝炎ウイルス阻害剤
CN105189495A (zh)*2013-03-152015-12-23先正达参股股份有限公司新颖的杀微生物剂
ES2735355T3 (es)2013-03-152019-12-18Gilead Sciences IncInhibidores macrocíclicos y bicíclicos de virus de hepatitis C
WO2016127859A1 (en)*2015-02-132016-08-18Sunshine Lake Pharma Co., Ltd.Compounds as hepatitis c inhibitors and uses thereof in medicine
CN108314648A (zh)*2018-04-122018-07-24苏州康润医药有限公司4-溴-7-氟异喹啉的合成方法
CN110305018B (zh)*2019-06-062022-07-15浙江普洛家园药业有限公司一种3-溴-2-氟硝基苯的制备方法
CN112358447B (zh)*2020-11-162022-04-12苏州康润医药有限公司7-氟异喹啉-1-羧酸的合成方法
CN114105800B (zh)*2021-11-252023-09-01杭州国瑞生物科技有限公司一种2,3-二氨基苯甲酸甲酯的制备方法
CN119143611A (zh)*2024-11-152024-12-17浙江大学衢州研究院一种n-异丙基对氟苯胺的连续制备方法

Family Cites Families (120)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US3547119A (en)1967-12-081970-12-15Baxter Laboratories IncCatheter assembly
US4211771A (en)1971-06-011980-07-08Robins Ronald KTreatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
US3798209A (en)*1971-06-011974-03-19Icn Pharmaceuticals1,2,4-triazole nucleosides
US4311137A (en)1980-04-301982-01-19Sherwood Medical Industries Inc.Infusion device
US4531937A (en)1983-01-241985-07-30Pacesetter Systems, Inc.Introducer catheter apparatus and method of use
CS263951B1 (en)*1985-04-251989-05-12Antonin Holy9-(phosponylmethoxyalkyl)adenines and method of their preparation
US4755173A (en)1986-02-251988-07-05Pacesetter Infusion, Ltd.Soft cannula subcutaneous injection set
US5354866A (en)1989-05-231994-10-11Abbott LaboratoriesRetroviral protease inhibiting compounds
US5696270A (en)1989-05-231997-12-09Abbott LaboratoriesIntermediate for making retroviral protease inhibiting compounds
GB8918806D0 (en)*1989-08-171989-09-27Shell Int ResearchChiral compounds,their preparation and use
US5310562A (en)1989-11-221994-05-10Margolin Solomon BComposition and method for reparation and prevention of fibrotic lesions
US5716632A (en)1989-11-221998-02-10Margolin; Solomon B.Compositions and methods for reparation and prevention of fibrotic lesions
US5518729A (en)1989-11-221996-05-21Margolin; Solomon B.Compositions and methods for reparation and prevention of fibrotic lesions
DE10199053I1 (de)1992-12-292002-08-29Abbott LabInhibitoren der retroviralen Protease
US5545143A (en)1993-01-211996-08-13T. S. I. MedicalDevice for subcutaneous medication delivery
US5624949A (en)*1993-12-071997-04-29Eli Lilly And CompanyProtein kinase C inhibitors
US6693072B2 (en)*1994-06-022004-02-17Aventis Pharmaceuticals Inc.Elastase inhibitors
US5756466A (en)*1994-06-171998-05-26Vertex Pharmaceuticals, Inc.Inhibitors of interleukin-1β converting enzyme
US6090822A (en)1995-03-032000-07-18Margolin; Solomon B.Treatment of cytokine growth factor caused disorders
US6232333B1 (en)1996-11-212001-05-15Abbott LaboratoriesPharmaceutical composition
US6323180B1 (en)*1998-08-102001-11-27Boehringer Ingelheim (Canada) LtdHepatitis C inhibitor tri-peptides
US6277830B1 (en)1998-10-162001-08-21Schering Corporation5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
US6608027B1 (en)*1999-04-062003-08-19Boehringer Ingelheim (Canada) LtdMacrocyclic peptides active against the hepatitis C virus
US7256005B2 (en)1999-08-102007-08-14The Chancellor, Masters And Scholars Of The University Of OxfordMethods for identifying iminosugar derivatives that inhibit HCV p7 ion channel activity
PL359359A1 (en)*2000-04-052004-08-23Schering CorporationMacrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties
PL358591A1 (en)*2000-04-192004-08-09Schering CorporationMacrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising alkyl and aryl alanine p2 moieties
HU229997B1 (en)*2000-07-212015-04-28Dendreon Corp San DiegoPeptides as ns3-serine protease inhibitors of hepatitis c virus
US7244721B2 (en)*2000-07-212007-07-17Schering CorporationPeptides as NS3-serine protease inhibitors of hepatitis C virus
ATE327246T1 (de)*2000-11-202006-06-15Bristol Myers Squibb CoHepatitis c tripeptid inhibitoren
ATE409181T1 (de)*2001-05-082008-10-15Univ YaleProteomimetische verbindungen und verfahren
US6867185B2 (en)*2001-12-202005-03-15Bristol-Myers Squibb CompanyInhibitors of hepatitis C virus
US7273885B2 (en)*2002-04-112007-09-25Vertex Pharmaceuticals IncorporatedInhibitors of serine proteases, particularly HCV NS3-NS4A protease
PL215228B1 (pl)*2002-05-202013-11-29Bristol Myers Squibb CoZwiazki tripeptydowe, ich zastosowanie i kompozycja farmaceutyczna je zawierajaca oraz jej zastosowanie
PL213029B1 (pl)*2002-05-202012-12-31Bristol Myers Squibb CoPodstawiona pochodna cykloalkilowa, zawierajaca ja kompozycja oraz ich zastosowanie
MY140680A (en)*2002-05-202010-01-15Bristol Myers Squibb CoHepatitis c virus inhibitors
PL211889B1 (pl)*2002-05-202012-07-31Bristol Myers Squibb CoPochodna heterocyklosulfonamidowa, kompozycja ją zawierająca oraz ich zastosowanie
PL199412B1 (pl)*2002-10-152008-09-30Boehringer Ingelheim IntNowe kompleksy rutenu jako (pre)katalizatory reakcji metatezy, pochodne 2-alkoksy-5-nitrostyrenu jako związki pośrednie i sposób ich wytwarzania
EP1615947A2 (en)*2003-04-102006-01-18Boehringer Ingelheim International GmbHProcess for preparing macrocyclic compounds
EP1613620A1 (en)*2003-04-112006-01-11Vertex Pharmaceuticals IncorporatedInhibitors of serine proteases, particularly hcv ns3-ns4a protease
ATE422895T1 (de)*2003-04-162009-03-15Bristol Myers Squibb CoMakrocyclische isochinolinpeptidinhibitoren des hepatitis-c-virus
ES2335887T3 (es)*2003-04-182010-04-06Enanta Pharmaceuticals, Inc.Compuestos macrociclicos de quinoxalinilo que inhiben las serina proteasas de la hepatitis c.
US7125845B2 (en)*2003-07-032006-10-24Enanta Pharmaceuticals, Inc.Aza-peptide macrocyclic hepatitis C serine protease inhibitors
CN101857631A (zh)*2003-10-102010-10-13沃泰克斯药物股份有限公司丝氨酸蛋白酶、特别是hcv ns3-ns4a蛋白酶的抑制剂
US7491794B2 (en)*2003-10-142009-02-17Intermune, Inc.Macrocyclic compounds as inhibitors of viral replication
CA2540858C (en)*2003-10-142009-12-08Intermune, Inc.Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication
US7939538B2 (en)*2004-06-282011-05-10Amgen Inc.Compounds, compositions and methods for prevention and treatment of inflammatory and immunoregulatory disorders and diseases
DE102004033312A1 (de)*2004-07-082006-01-26Boehringer Ingelheim Pharma Gmbh & Co. KgKontinuierliches Metatheseverfahren mit Ruthenium-Katalysatoren
CA2573346C (en)*2004-07-202011-09-20Boehringer Ingelheim International GmbhHepatitis c inhibitor peptide analogs
EP1797111B1 (en)*2004-08-272011-06-22Schering CorporationAcylsulfonamide compounds as inhibitors of hepatitis c virus ns3 serine protease
EP1794179A1 (en)*2004-09-172007-06-13Boehringer Ingelheim International GmbhRing-closing metathesis process in supercritical fluid
WO2006119061A2 (en)*2005-05-022006-11-09Merck & Co., Inc.Hcv ns3 protease inhibitors
US7608592B2 (en)*2005-06-302009-10-27Virobay, Inc.HCV inhibitors
US7601686B2 (en)*2005-07-112009-10-13Bristol-Myers Squibb CompanyHepatitis C virus inhibitors
TWI389908B (zh)*2005-07-142013-03-21Gilead Sciences Inc抗病毒化合物類
AR057456A1 (es)*2005-07-202007-12-05Merck & Co IncInhibidores de la proteasa ns3 del vhc
EP1924594A2 (en)2005-07-252008-05-28Intermune, Inc.Novel macrocyclic inhibitors of hepatitis c virus replication
HRP20110885T1 (hr)*2005-07-292011-12-31Tibotec PharmaceuticalsMakrociklički inhibitori virusa hepatitisa c
PE20070211A1 (es)*2005-07-292007-05-12Medivir AbCompuestos macrociclicos como inhibidores del virus de hepatitis c
EP2402331A1 (en)*2005-08-022012-01-04Vertex Pharmaceuticals IncorporatedInhibitors of serine proteases
EA200801050A1 (ru)*2005-10-112008-12-30Интермьюн, Инк.Соединения и способы ингибирования репликации вирусного гепатита с
US7772183B2 (en)*2005-10-122010-08-10Bristol-Myers Squibb CompanyHepatitis C virus inhibitors
WO2007057317A1 (en)*2005-11-162007-05-24F. Hoffmann-La Roche AgNovel pyrrolidine derivatives as inhibitors of coagulation factor xa
US7728148B2 (en)*2006-06-062010-06-01Enanta Pharmaceuticals, Inc.Acyclic oximyl hepatitis C protease inhibitors
KR20090024834A (ko)*2006-07-052009-03-09인터뮨, 인크.Ｃ형 간염 바이러스 복제의 신규 억제제
EP2049474B1 (en)*2006-07-112015-11-04Bristol-Myers Squibb CompanyHepatitis c virus inhibitors
CA2657618C (en)*2006-07-132016-10-11Achillion Pharmaceuticals, Inc.4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
US7718612B2 (en)*2007-08-022010-05-18Enanta Pharmaceuticals, Inc.Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors
CA2656816A1 (en)*2006-08-042008-02-14Enanta Pharmaceuticals, Inc.Tetrazolyl macrocyclic hepatitis c serine protease inhibitors
US20090035267A1 (en)*2007-07-312009-02-05Moore Joel DAcyclic, pyridazinone-derived hepatitis c serine protease inhibitors
US7635683B2 (en)*2006-08-042009-12-22Enanta Pharmaceuticals, Inc.Quinoxalinyl tripeptide hepatitis C virus inhibitors
US20080038225A1 (en)*2006-08-112008-02-14Ying SunTriazolyl acyclic hepatitis c serine protease inhibitors
US7687459B2 (en)*2006-08-112010-03-30Enanta Pharmaceuticals, Inc.Arylalkoxyl hepatitis C virus protease inhibitors
US7662779B2 (en)*2006-08-112010-02-16Enanta Pharmaceuticals, Inc.Triazolyl macrocyclic hepatitis C serine protease inhibitors
US7582605B2 (en)*2006-08-112009-09-01Enanta Pharmaceuticals, Inc.Phosphorus-containing hepatitis C serine protease inhibitors
US7605126B2 (en)*2006-08-112009-10-20Enanta Pharmaceuticals, Inc.Acylaminoheteroaryl hepatitis C virus protease inhibitors
US20090035268A1 (en)*2007-08-012009-02-05Ying SunTetrazolyl acyclic hepatitis c serine protease inhibitors
US20090098085A1 (en)*2006-08-112009-04-16Ying SunTetrazolyl acyclic hepatitis c serine protease inhibitors
US20080107625A1 (en)*2006-11-012008-05-08Bristol-Myers Squibb CompanyInhibitors of Hepatitis C Virus
US8343477B2 (en)*2006-11-012013-01-01Bristol-Myers Squibb CompanyInhibitors of hepatitis C virus
US7772180B2 (en)*2006-11-092010-08-10Bristol-Myers Squibb CompanyHepatitis C virus inhibitors
EA200970493A1 (ru)*2006-11-172009-10-30Тиботек Фармасьютикалз Лтд.Макроциклические ингибиторы вируса гепатита с
EP2125870A4 (en)*2007-02-162011-04-06Boehringer Ingelheim Int INHIBITORS OF HEPATITIS C NS3 PROTEASE
US20100074867A1 (en)*2007-03-232010-03-25Schering Corporation Patent Department, K-6-1; 1990P1-nonepimerizable ketoamide inhibitors of hcv ns3 protease
US20090123423A1 (en)*2007-04-262009-05-14Yonghua GaiHydroxyamic analogs as hepatitis c virus serine protease inhibitor
SG174809A1 (en)2007-05-032011-10-28Intermune IncMacrocyclic compounds useful as inhibitors of hepatitis c virus
JP2010526146A (ja)*2007-05-042010-07-29ブリストル−マイヤーズ スクイブ カンパニー［６，５］−二環式ｇｐｒ１１９ｇタンパク質結合受容体アゴニスト
AU2008251425A1 (en)*2007-05-102008-11-20Array Biopharma, Inc.Novel peptide inhibitors of hepatitis C virus replication
US20090005387A1 (en)*2007-06-262009-01-01Deqiang NiuQuinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors
BRPI0813733A2 (pt)*2007-06-292019-11-05Gilead Sciences Inccomposto com atividade inibidora de hcv, sua composição farmacêutica e seu uso.
WO2009014730A1 (en)*2007-07-262009-01-29Idenix Pharmaceuticals, Inc.Macrocyclic serine protease inhibitors
US20090053175A1 (en)*2007-08-242009-02-26Yat Sun OrSubstitute pyrrolidine derivatives
US20090060874A1 (en)*2007-09-052009-03-05Yao-Ling QiuBicyclic pyrrolidine derivatives
US8163693B2 (en)*2007-09-242012-04-24Achillion Pharmaceuticals, Inc.Urea-containing peptides as inhibitors of viral replication
US20090082366A1 (en)*2007-09-262009-03-26Protia, LlcDeuterium-enriched telaprevir
AU2008309589B2 (en)*2007-10-102012-07-05Novartis AgSpiropyrrolidines and their use against HCV and HIV infection
WO2009055335A2 (en)*2007-10-252009-04-30Taigen Biotechnology Co., Ltd.Hcv protease inhibitors
US8383583B2 (en)*2007-10-262013-02-26Enanta Pharmaceuticals, Inc.Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors
WO2009067225A2 (en)*2007-11-202009-05-28Concert Pharmaceuticals, Inc.Boceprevir derivatives for the treatment of hcv infections
ES2599927T3 (es)*2007-12-212017-02-06F. Hoffmann-La Roche AgProceso para la preparación de un macrociclo
AP2010005416A0 (en)*2008-04-152010-10-31Intermune IncNovel macrocyclic inhibitors of hepatitis c virus replication.
EP2307434B1 (en)*2008-07-022014-02-12IDENIX Pharmaceuticals, Inc.Compounds and pharmaceutical compositions for the treatment of viral infections
US7906655B2 (en)*2008-08-072011-03-15Bristol-Myers Squibb CompanyHepatitis C virus inhibitors
BRPI0916609A2 (pt)*2008-08-072015-08-04Hoffmann La RocheProcesso para a preparação de um macrociclo
UY32099A (es)*2008-09-112010-04-30Enanta Pharm IncInhibidores macrocíclicos de serina proteasas de hepatitis c
AU2009293493B2 (en)*2008-09-172014-09-18Boehringer Ingelheim International GmbhCombination of HCV NS3 protease inhibitor with interferon and ribavirin
US8603737B2 (en)*2008-09-192013-12-10Celgene Avilomics Research, Inc.Methods for identifying HCV protease inhibitors
US20100080770A1 (en)*2008-09-292010-04-01Bristol-Myers Squibb CompanyHepatitis C Virus Inhibitors
US8044087B2 (en)*2008-09-292011-10-25Bristol-Myers Squibb CompanyHepatitis C virus inhibitors
US8563505B2 (en)*2008-09-292013-10-22Bristol-Myers Squibb CompanyHepatitis C virus inhibitors
CA2740728A1 (en)*2008-10-152010-04-22Intermune, Inc.Therapeutic antiviral peptides
AU2009316472B2 (en)*2008-11-202015-07-09Achillion Pharmaceuticals, Inc.Cyclic carboxamide compounds and analogues thereof as of Hepatitis C virus
US20110064694A1 (en)*2009-09-092011-03-17Yale UniversityAnti-hepatitis c activity of meso-tetrakis-porphyrin analogues
US8703938B2 (en)*2009-09-112014-04-22Enanta Pharmaceuticals, Inc.Hepatitis C virus inhibitors
US8927709B2 (en)*2009-09-112015-01-06Enanta Pharmaceuticals, Inc.Hepatitis C virus inhibitors
US8759332B2 (en)*2009-09-112014-06-24Enanta Pharmaceuticals, Inc.Hepatitis C virus inhibitors
US8822700B2 (en)*2009-09-112014-09-02Enanta Pharmaceuticals, Inc.Hepatitis C virus inhibitors
WO2011031904A1 (en)*2009-09-112011-03-17Enanta Pharmaceuticals, IncHepatitis c virus inhibitors
US8815928B2 (en)*2009-09-112014-08-26Enanta Pharmaceuticals, Inc.Hepatitis C virus inhibitors
AU2009352688B2 (en)*2009-09-152014-04-17Taigen Biotechnology Co., Ltd.HCV protease inhibitors
US20110082182A1 (en)*2009-10-012011-04-07Intermune, Inc.Therapeutic antiviral peptides

Also Published As

Publication numberPublication date
WO2011038293A1 (en)2011-03-31
AU2010298028A2 (en)2012-10-04
US20110081315A1 (en)2011-04-07
AU2010298028A1 (en)2012-04-19
TW201124137A (en)2011-07-16
CN105001302A (zh)2015-10-28
IL218766A0 (en)2012-06-28
CN102741270B (zh)2015-07-22
EP2483290A4 (en)2013-05-01
MA33720B1 (fr)2012-11-01
CO6531497A2 (es)2012-09-28
JP2013505952A (ja)2013-02-21
CN102741270A (zh)2012-10-17
AR078462A1 (es)2011-11-09
EP2483290A1 (en)2012-08-08
EA201290128A1 (ru)2013-01-30
IN2012DN02693A (es)2015-09-04
PH12012500602A1 (en)2017-08-23
CA2775697A1 (en)2011-03-31
TN2012000135A1 (en)2013-09-19
MX2012003500A (es)2012-08-01
KR20130026410A (en)2013-03-13

Similar Documents

PublicationPublication DateTitle
ECSP12011845A (es)Nuevos inhibidores macrocíclicos de la replicación
ECSP099780A (es)Nuevos inhibidores macrociclicos de la replicacion del virus de hepatitis c
ECSP10010612A (es)Nuevos inhibidores macrociclicos de la replicacion del virus de la hepatitis c
ECSP099792A (es)Nuevos peptidos inhibidores de la replicacion del virus de hepatitis c
ECSP14013217A (es)4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il-benzamidas como inhibidores de btk.
CU20090209A7 (es)Compuestos macrocíclicos como inhibidores de la replicación viral
UY37997A (es)Agentes antivirales contra la hepatitis b
MX2009008439A (es)Nuevos inhibidores de la replicacion del virus de hepatitis c.
AR055095A1 (es)Nuevos inhibidores macrociclicos de la replicacion del virus de la hepatitis c
ECSP14013315A (es)Inhibidores de aplicación viral
DOP2014000133A (es)Triazolopiridinas sustituidas
MX2012003171A (es)Novedosos inhibidores macrociclicos de la replicacion del virus de hepatitis c.
ECSP13012417A (es)Derivados de ácido napht-2-ilacético para tratar sida
ECSP12011610A (es)Inhibidores de la replicación de los virus de la gripe
UY32793A (es)Compuestos inhibidores de los virus flaviviridae, composición farmacéutica que los contiene y sus usos
AR084237A1 (es)Metodos para tratar virus de hepatitis c (hcv), composicion
CO6592102A2 (es)Compuestos de sililo triciclicos fusionados y metodos de uso de los mismos para el tratamiento de enfermedades virales
CO6761335A2 (es)Inhibidores del virus de la hepatitis c
BR112012023021A2 (pt)compostos de indazol e seus usos
ECSP14013189A (es)Inhibidores de la replicación de los virus de la gripe
EA201490228A1 (ru)Новые производные трифторметилоксадиазола и их применение для лечения заболевания
ECSP13013011A (es)Triazolopiridinas
UY34066A (es)Inhibidores del virus de la hepatitis c
UY33452A (es)Triazolopiridinas sustituidas
BR112012033675A2 (pt)derivado de benzofurano para o tratamento de hepatite c
[8]ページ先頭
©2009-2025 Movatter.jp